AstraZeneca have appointed BioCity to establish a new centre for bioscience companies at their Alderley Park site in Cheshire. The new BioHub has 36,000 sq ft of high-end laboratory and office facilities for early-stage and growing firms engaged in innovative drug discovery and development. Demand for accommodation is expected to be competitive with tenant companies already having moved in.
Conversations between BioCity and AstraZeneca began in 2012 when they begun exploring opportunities to create a specialist centre for upcoming life science companies.
Dr Glenn Crocker, CEO of BioCity Nottingham Limited, has led the discussions with AstraZeneca: “We bring many years of experience in developing thriving communities of successful life science companies and look forward to working closely with the AstraZeneca management team. I believe we now have a unique opportunity to build connections between tenant companies based at Alderley Park, Nottingham and Scotland which could ultimately transform the way life science innovation is achieved.”
Speaking on behalf of AstraZeneca, Clive Morris, AstraZeneca Vice President, Research & Development said, “We are delighted to welcome three innovation-driven companies to Alderley Park. I am confident that with BioCity’s experience in this area we can continue to seek further opportunities to attract future investment and build on the existing world class facilities available at Alderley Park.”.